In a new study, researchers found that prescribed CBD could help people quit cannabis.
They found that prescribed doses of the non-intoxicating constituent part of the cannabis plant could help people kick the habit.
This is the first-ever randomized clinical trial of CBD for cannabis use disorder.
The research was conducted by a team at the University of Bath.
Cannabis is now the primary drug cited by first-time clients presenting at addiction services across Europe, with the number of people entering treatment increasing by 76% over the past decade.
The increase in treatment for cannabis problems has occurred alongside an increase in concentrations of THC, the intoxicating component of cannabis.
Daily use of cannabis with high THC concentrations is associated with a five-times increased risk of psychosis.
In the study, the researchers administered CBD or placebo to 82 volunteers who were motivated to quit using cannabis but had previously failed to do so.
They measured the effects of the drug on levels of cannabis use both during a four-week treatment period and up to six months follow-up.
As this was the first clinical trial to assess CBD for reducing cannabis use, they tested three different doses of CBD in an adaptive design to find out which doses might be most effective:
In the first stage of the trial, 48 volunteers received either placebo or CBD at doses of 200mg, 400mg or 800mg. The researchers found that the lowest dose of 200mg CBD was ineffective and so they dropped it from the trial.
In the second stage of the trial, the researchers recruited an additional 34 volunteers to receive either placebo, 400mg or 800mg CBD.
At the end of the trial, they found consistent evidence that CBD at 400mg or 800mg was more effective than a placebo at reducing cannabis use.
Their results showed that participants treated with CBD showed lower levels of cannabis in their urine and an increased number of days abstinent compared to those treated with placebo.
CBD was well tolerated at all doses and there were no increases in side effects compared to placebo. 94% of the volunteers completed treatment.
Importantly, the doses of CBD tested were significantly higher than CBD products purchased online or from the High Street (typically 25mg per day).
All participants in the trial met a clinical diagnosis of cannabis use disorder, indicating a problematic pattern of cannabis use which had created strong impairment and distress for the individual.
All participants had previously failed to quit cannabis use at least once and took part in the trial as part of a cessation attempt.
The results open up a novel treatment for managing problematic cannabis use in clinical settings.
CBD at daily oral doses of 400mg and 800mg has the potential to address the substantial and currently unmet clinical need for a pharmacological treatment of cannabis use disorders.
One author of the study is Dr. Tom Freeman, Director of the Addiction and Mental Health Group within the Department of Psychology.
The study is published in Lancet Psychiatry.
Copyright © 2020 Knowridge Science Report. All rights reserved.
